Literature DB >> 9645385

Suppression of experimental autoimmune encephalomyelitis with a TNF binding protein (TNFbp) correlates with down-regulation of VCAM-1/VLA-4.

K Selmaj1, A Walczak, M Mycko, T Berkowicz, T Kohno, C S Raine.   

Abstract

The effect of a novel TNF binding protein (TNFbp), a polyethylene glycol-linked form of the type I soluble receptor of TNF, on the expression of adhesion molecules has been investigated with a passive transfer model of experimental autoimmune encephalomyelitis (EAE) in SJL/J mice. The expression of L-selectin, VLA-4 and LFA-1 on spleen cells of EAE animals treated with TNFbp or saline was examined by FACS analysis. The expression of VCAM-1 and ICAM-1 was investigated by immunochemistry in spinal cord tissue of SJL/J mice with EAE. In animals sensitized for EAE and treated with TNFbp, the expression of VCAM-1 in the central nervous system as well as VLA-4 on spleen cells was clearly diminished. Reduction in VCAM-1 staining and VLA-4 expression corresponded to inhibition of inflammation in the spinal cord and to prevention of clinical signs of EAE. The results have also shown that myelin basic protein responses as well as non-antigen-specific responses were not diminished in animals treated with TNFbp. The findings suggest that TNFbp might prevent EAE development by modulating the expression of VCAM-1 and VLA-4.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645385     DOI: 10.1002/(SICI)1521-4141(199806)28:06<2035::AID-IMMU2035>3.0.CO;2-A

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

Review 1.  Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system.

Authors:  K W Selmaj
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  TNF-alpha antagonism generates a population of antigen-specific CD4+CD25+ T cells that inhibit protective immunity in murine histoplasmosis.

Authors:  George S Deepe; Reta S Gibbons
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

Review 3.  Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease.

Authors:  Benjamin M Segal
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919

4.  Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents.

Authors:  Ryuji Ohashi; Ryuji Fukazawa; Makoto Watanabe; Hanako Tajima; Noriko Nagi-Miura; Naohito Ohno; Shinichi Tsuchiya; Yuh Fukuda; Shunichi Ogawa; Yasuhiko Itoh
Journal:  Int J Vasc Med       Date:  2013-03-31

Review 5.  PEGylated drugs in rheumatology--why develop them and do they work?

Authors:  Thomas McDonnell; Yiannis Ioannou; Anisur Rahman
Journal:  Rheumatology (Oxford)       Date:  2013-08-20       Impact factor: 7.580

Review 6.  Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.

Authors:  Justin R Siebert; Amanda Conta Steencken; Donna J Osterhout
Journal:  Biomed Res Int       Date:  2014-09-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.